EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response

Li Liu, Peng Wu, Bingzhi Wang, Jiyan Dong, Chaoqi Zhang, Wenchao Liu, Jianming Ying

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-03985-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Li Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and…. Hauptthemen laut MEDLINE: Receptors, Immunologic, Lung Neoplasms, Small Cell Lung Carcinoma, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Health Commission, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) is a novel immune checkpoint playing a crucial role in immunosuppression and immune evasion. This study aims to elucidate the expression patterns, characteristics, and possible mechanisms of TIGIT in small cell lung cancer (SCLC). METHODS: TIGIT expression was analyzed across various cancers and normal tissues using The Cancer Genome Atlas (TCGA). Transcriptomic data from SCLC patients, sourced from the Gene Expression Omnibus (GEO) and literature, were analyzed to assess TIGIT-related characteristics. Immunohistochemistry (IHC) was used to verify TIGIT expression in post-surgical and advanced SCLC samples, focusing on expression characteristics, prognostic value, and treatment response. RESULTS: TIGIT was significantly overexpressed in various tumors, including SCLC (p < 0.05). Higher expression was associated with better overall survival (OS) (p < 0.05). Notably, a significant positive correlation was observed between TIGIT expression and immune-related metagenes, such as HCK, interferon, and LCK (p < 0.05). Immune infiltration analysis revealed a strong positive correlation between TIGIT expression and immune score in multiple cohorts. Additionally, TIGIT expression correlated positively with immune cells, including CD8 T cells, cytotoxic lymphocytes, and B cells (p < 0.05), and multiple immune checkpoints like BTLA, ICOS, and LAG3 (p < 0.05), while it had a significant negative correlation with the TIDE score (p < 0.05). In the validation section, patients with high TIGIT expression showed significantly prolonged disease-free survival (DFS) and OS (p < 0.05), and demonstrated a better response to adjuvant chemotherapy (ACT) and immunotherapy. CONCLUSION: TIGIT serves as a biomarker in SCLC, with its high expression indicating favorable prognosis and treatment response. These effects may be due to TIGIT's unique immune landscape and its association with other immune checkpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicLung NeoplasmsSmall Cell Lung CarcinomaImmunotherapyBiomarkers, TumorHumansPrognosisMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

CheckpointImmunotherapyPD-L1/PD-1PrognosisSmall cell lung cancerTIGIT

Substanzen

TIGIT protein, humanReceptors, ImmunologicBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. jmying@cicams.a…

Förderung

  • National Natural Science Foundation of China
  • Beijing Municipal Health Commission
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences

Zitieren

APA

Liu, L., Wu, P., Wang, B., Dong, J., Zhang, C., Liu, W., & Ying, J. (2025). Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03985-6

Vancouver

Liu L, Wu P, Wang B, Dong J, Zhang C, Liu W, et al. Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03985-6

BibTeX
@article{Liu2025,
  author = {Liu, Li and Wu, Peng and Wang, Bingzhi and Dong, Jiyan and Zhang, Chaoqi and Liu, Wenchao and Ying, Jianming},
  title = {Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-03985-6}
}
Kostenlos starten →